Global Viscosupplementation Market Size (2024 - 2029)

The viscosupplementation market is anticipated to experience growth, driven by an increasing patient population suffering from osteoarthritis and the introduction of advanced products. The market's expansion was initially hindered by the COVID-19 pandemic, which led to a decline in hospital visits and non-emergency procedures due to lockdowns. However, as restrictions have eased and procedures have resumed, the market is expected to recover. Despite these positive trends, regulatory challenges and a lack of awareness about viscosupplementation may pose obstacles to market growth.

Home Market Analysis Healthcare Research Pharmaceuticals Research Non regulated Drugs Research Viscosupplementation Industry Market Size

Market Size of Global Viscosupplementation Industry

Viscosupplementation Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 5.80 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Viscosupplementation Market Major Players

*Disclaimer: Major Players sorted in no particular order

Viscosupplementation Market Analysis

The viscosupplementation market is projected to grow with a CAGR of 5.8% during the forecast period (2022 - 2027).

The emergence of the COVID-19 pandemic had its impact on the viscosupplementation market due to the decline in visits to hospitals and ambulatory surgical centers because of lockdown restrictions imposed by various governments globally. Due to these restrictions, non-emergency procedures were halted in the hospitals, which have impacted the patient's life. For instance, according to a study published in the Clinical Pharmacology and Therapeutics Journal in May 2020 by Enrico Ragni et al., the presence of osteoarthritis-related concomitant disorders is expected to initiate life-threatening risks for osteoarthritis patients in the event of SARS-CoV2 viral infection. This has prompted clinicians and orthopedists to carefully check and evaluate osteoarthritis patients, not just for symptom management but also for comorbidities that may arise as a result of osteoarthritis treatment during the COVID-19 pandemic. As a result of the aforementioned factors, the market under study is projected to be impacted during the pandemic era. However, with the resumed procedures and increased hospital visits, and lessening of COVID-19 restrictions, the market is expected to gain its potential over the period.

Certain factors that are driving the market growth include the rising patient pool suffering from osteoarthritis and the increasing introduction of advanced and combination products. For instance, according to an article published by the Centers for Disease Control and Prevention in April 2020, titled "Osteoarthritis", about 32.5 million people in the United States are suffering from osteoarthritis. In addition to this, 62% of women suffer from osteoarthritis. Similarly, according to an article published by the National Center for Biotechnology Information, in January 2021, titled "Prevalence of knee osteoarthritis, its determinants, and impact on the quality of life in elderly persons in rural Ballabgarh, Haryana", it has been observed that 64.3% of the elder population is suffering from knee osteoarthritis and the elderly patients with knee osteoarthritis have considerably poorer quality-of-life. Furthermore, obesity is another risk factor contributing to orthopedic conditions. For instance, according to an article published by the National Center for Biotechnology Information, in 2021, titled 'Prevalence of Obesity in India and its Neurological Implications: A Multifactor Analysis of a Nationwide Cross-Sectional Study,': the prevalence rate of obesity in India is found to be 40.3%. In addition to this, it has been that the highest rate of prevalence is found in South India with 46.51%, and the lowest in East India with 32.96%. Thus, the increasing burden of osteoarthritis in patients is likely to increase the demand for viscosupplementation procedures, which reduces the pain in joints by increasing the lubrication between them, thereby increasing the market growth over the forecast period.

However, the regulatory issues and lack of awareness regarding the viscosupplementation are likely to restrain the market expansion.

Viscosupplementation Industry Segmentation

As per the scope of the report, Viscosupplements are the injection of hyaluronic acid which injects into diarthrodial joints, intending to restore the rheological properties of the synovial fluid, thereby producing analgesia, mechanical, chondroprotective, and anti-inflammatory effects. Viscosupplements are usually preferred by healthcare providers to treat osteoarthritis, but then it may also benefit patients with certain other kinds of arthritis, such as rheumatoid arthritis. The Global Viscosupplementation market is segmented by Dosage (Single Injection, Three injections, Five Injections), End-User (Hospitals, Ambulatory Surgical Centers, Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Dosage
Single Injection
Three Injection
Five Injection
By End-User
Hospitals
Ambulatory Surgical Centers
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Viscosupplementation Market Size Summary

The viscosupplementation market is poised for significant growth, driven by an increasing patient population suffering from osteoarthritis and the introduction of advanced and combination products. The market experienced a temporary setback due to the COVID-19 pandemic, which led to a decline in hospital visits and the postponement of non-emergency procedures. However, as restrictions have eased and procedures have resumed, the market is expected to regain its momentum. The demand for viscosupplementation is further bolstered by the rising prevalence of osteoarthritis, particularly among the elderly and those with obesity, which necessitates procedures that enhance joint lubrication and reduce pain. Despite challenges such as regulatory issues and limited awareness, the market is expected to expand, with a notable focus on single injection products that offer convenience and cater to the growing demand for outpatient surgeries.

North America is anticipated to lead the global viscosupplementation market, supported by a well-developed healthcare infrastructure, a rising geriatric population, and an increasing prevalence of arthritis-related disorders. The demand for non-surgical procedures is on the rise, driven by the growing number of individuals experiencing arthritis and knee pain. The market's growth is further fueled by the strategic efforts of companies to develop and launch new viscosupplement products, such as single-injection therapies, which are gaining traction due to their ease of use and effectiveness. The competitive landscape is characterized by the presence of major players engaging in partnerships, product launches, and collaborations to maintain their market position. These dynamics, coupled with the increasing burden of arthritis and related conditions, are expected to propel the market forward over the forecast period.

Explore More

Global Viscosupplementation Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Patient Pool Suffering from Osteoarthritis

      2. 1.2.2 Introduction of Advanced and Combination Products

    3. 1.3 Market Restraints

      1. 1.3.1 Regulatory Issues and Lack of Awareness

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Dosage

      1. 2.1.1 Single Injection

      2. 2.1.2 Three Injection

      3. 2.1.3 Five Injection

    2. 2.2 By End-User

      1. 2.2.1 Hospitals

      2. 2.2.2 Ambulatory Surgical Centers

      3. 2.2.3 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Viscosupplementation Market Size FAQs

The Global Viscosupplementation Market is projected to register a CAGR of 5.80% during the forecast period (2024-2029)

Fidia Farmaceutici s.p.a. , Ferring Pharmaceuticals, Anika Therapeutics, Inc., Bioventus LLC and Sanofi SA are the major companies operating in the Global Viscosupplementation Market.

Viscosupplementation Market Report Snapshots

Viscosupplementation Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)